Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2020-05-13
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai
NCT05422963
CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome
NCT03064464
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
NCT05306223
Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice
NCT01212601
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
NCT07268664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hemorrhagic fever with renal syndrome, also known as epidemic hemorrhagic fever, is an infectious disease caused by the Hantavirus. The main clinical features are fever, exudation, hemorrhage, hypotensive shock, and kidney damage. It was once epidemic viral infection in China after viral hepatitis. In the 1980s, the number of cases reported exceeded 100,000. More than 1650,000 patients have been reported in China since 1950, including more than 47,000 deaths, with a total case fatality rate of approximately 2.89%. The number of people in the province accounted for more than 80% of the total number of people in the country. From 2004 to 2015, Shaanxi Province and the three northeastern provinces were the hardest hit areas of national hemorrhagic fever.
There are reports of sporadic leishmaniasis in China, but they are rare and lack corresponding epidemiological data. In 2015, 507 new cases of visceral leishmaniasis were reported, which was a high level in the past 10 years. However, the incidence rate remains at a low level of 0.0372/100,000. In recent years, visceral leishmaniasis is mainly distributed in the northwestern part of China, and there are many cases reported in the southwestern part of the country. The three areas with the highest incidence rate are Xinjiang Uygur Autonomous Region, Gansu Province and Sichuan Province. The cases in non-endemic areas are mainly adults who go to work in popular areas, and mainly male physical workers, while the popular areas are mainly infants and young children.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
kala-azar group
Antibiotics
Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
epidemic hemorrhagic fever group
Antibiotics
Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
brucellosis group
Antibiotics
Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotics
Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. sample culture: Brucella;
2. Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever：
1 specific antibody positive 2 Hantavirus RNA positive kala-azar：
1. latent infection: rK39 antibody positive
2. patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)
Exclusion Criteria
2. HIV antibody positive and AIDS patients
3. Patients who participated in other clinical trials during the same period.
4. Pregnant, lactating women or women of childbearing age who are ready to conceive.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Xinjiang Medical University
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
The ninth Hospital of NanChang city
UNKNOWN
Luoyang Central Hospital
OTHER
Second Affiliated Hospital of Nanchang University
OTHER
The Fifth Affiliated Hospital Xinjiang Medical University
UNKNOWN
LanZhou University
OTHER
Huzhou Central Hospital
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
Fuzhou Municipal Infectious Diseases Hospital
UNKNOWN
Henan Provincial People's Hospital
OTHER
The First Affiliated Hospital of Lanzhou Medical University
UNKNOWN
Linyi People's Hospital
OTHER
Nantong University
OTHER
Nanyang Central Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Qianfoshan Hospital
OTHER
Infectious Hospital of Jining City
UNKNOWN
The Affiliated Hospital of Jining Medical University and Zaozhuang City
UNKNOWN
The First Affiliated Hospital of Shanxi Medical University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
People's Hospital of Xinjiang Uygur Autonomous Region
OTHER
Yuncheng Central Hospital
OTHER
Zibo Central Hospital
OTHER_GOV
The Second Affiliated Hospital of Henan Medical University
UNKNOWN
West Hospital of the First Affiliated Hospital of Guangxi University
UNKNOWN
The First Hospital of Jilin University
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
The Second Hospital of Shandong University
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Huashan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wen-hong Zhang
Chief of dpartment of infectious disease
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Li D, Yuan G, Wang YO, Wang H, Zhang Q, Wang YA, Gu Y, Zhang H, Zhang Y, Song J, Fu Z, Lin K, Qiu C, Zhou Y, Fan M, Zhao Y, Guo J, Jiang N, Ai J, Liu H, Zhang W. Clinical Characteristics, Treatment, and Prognosis of Osteoarticular Brucellosis: A Retrospective Real-World Study in Shenyang, China, 2014-2019. Foodborne Pathog Dis. 2025 Feb;22(2):86-96. doi: 10.1089/fpd.2023.0027. Epub 2024 Apr 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY2019-RWS(CID)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.